Cargando…

PTPRS drives adaptive resistance to MEK/ERK inhibitors through SRC

PTPRS is the most commonly mutated receptor tyrosine phosphatase in colorectal cancer (CRC). PTPRS has been shown to directly affect ERK and regulate its activation and nuclear localization. Here we identify that PTPRS may play a significant role in developing adaptive resistance to MEK/ERK inhibito...

Descripción completa

Detalles Bibliográficos
Autores principales:	Davis, Thomas B., Yang, Mingli, Wang, Heiman, Lee, Changgong, Yeatman, Timothy J., Pledger, W. Jack
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2019
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6887575/ https://www.ncbi.nlm.nih.gov/pubmed/31827720 http://dx.doi.org/10.18632/oncotarget.27335

Ejemplares similares

PTPRS Regulates Colorectal Cancer RAS Pathway Activity by Inactivating Erk and Preventing Its Nuclear Translocation
por: Davis, Thomas B., et al.
Publicado: (2018)

An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy
por: Yang, Mingli, et al.
Publicado: (2022)

Ras Pathway Activation and MEKi Resistance Scores Predict the Efficiency of MEKi and SRCi Combination to Induce Apoptosis in Colorectal Cancer
por: Davis, Thomas Benjamin, et al.
Publicado: (2022)

High expression of protein tyrosine phosphatase receptor S (PTPRS) is an independent prognostic marker for cholangiocarcinoma
por: Lertpanprom, Muntinee, et al.
Publicado: (2022)

APC and TP53 Mutations Predict Cetuximab Sensitivity across Consensus Molecular Subtypes
por: Thota, Ramya, et al.
Publicado: (2021)

Oncogenic RAC1 and NRAS drive resistance to endoplasmic reticulum stress through MEK/ERK signalling
por: Bright, Michael D., et al.
Publicado: (2018)

Integrin β5 contributes to the tumorigenic potential of breast cancer cells through Src-FAK and MEK-ERK signaling pathways
por: Bianchi-Smiraglia, Anna, et al.
Publicado: (2012)

Concurrent inhibition of FAK/SRC and MEK overcomes MEK inhibitor resistance in Neurofibromatosis Type I related malignant peripheral nerve sheath tumors
por: Gu, Yihui, et al.
Publicado: (2022)

MEK inhibitor resistance in lung adenocarcinoma is associated with addiction to sustained ERK suppression
por: Farnsworth, Dylan A., et al.
Publicado: (2022)

Pathway profiling of a novel SRC inhibitor, AZD0424, in combination with MEK inhibitors for cancer treatment
por: Dawson, John C., et al.
Publicado: (2021)

MEK Inhibitor U0126 Reverses Protection of Axons from Wallerian Degeneration Independently of MEK–ERK Signaling
por: Evans, Catherine, et al.
Publicado: (2013)

Combining MEK and SRC inhibitors for treatment of colorectal cancer demonstrate increased efficacy in vitro but not in vivo
por: Fan, Fan, et al.
Publicado: (2023)

PTEN deletion drives acute myeloid leukemia resistance to MEK inhibitors
por: Smith, Amanda M., et al.
Publicado: (2019)

Managing Acquired Resistance to Third-Generation EGFR Tyrosine Kinase Inhibitors Through Co-Targeting MEK/ERK Signaling
por: Yu, Danlei, et al.
Publicado: (2021)

Erratum: PTEN deletion drives acute myeloid leukemia resistance to MEK inhibitors
por: Smith, Amanda M., et al.
Publicado: (2020)

The MEK inhibitors enhance the efficacy of sorafenib against hepatocellular carcinoma cells through reducing p-ERK rebound
por: Hou, Wanting, et al.
Publicado: (2019)

Combination of MEK and SRC inhibition suppresses melanoma cell growth and invasion
por: Ferguson, Jennifer, et al.
Publicado: (2012)

MEK/ERK addiction in CNL/aCML
por: Kesarwani, Meenu, et al.
Publicado: (2017)

A Predictive Model of Adaptive Resistance to BRAF/MEK Inhibitors in Melanoma
por: Ruiz, Emmanuelle M., et al.
Publicado: (2023)

The Extract of Rhodobacter sphaeroides Inhibits Melanogenesis through the MEK/ERK Signaling Pathway
por: Liu, Wen-Sheng, et al.
Publicado: (2013)

GBP5 drives malignancy of glioblastoma via the Src/ERK1/2/MMP3 pathway
por: Yu, Xiaoting, et al.
Publicado: (2021)

Generation and characterization of MEK and ERK inhibitors- resistant non-small-cells-lung-cancer (NSCLC) cells
por: Iezzi, Alice, et al.
Publicado: (2018)

POU4F1 promotes the resistance of melanoma to BRAF inhibitors through MEK/ERK pathway activation and MITF up-regulation
por: Liu, Lin, et al.
Publicado: (2020)

BRAF/MEK inhibitors promote CD47 expression that is reversible by ERK inhibition in melanoma
por: Liu, Fen, et al.
Publicado: (2017)

In Vitro and In Vivo Efficacies of the EGFR/MEK/ERK Signaling Inhibitors in the Treatment of Alveolar Echinococcosis
por: Cheng, Zhe, et al.
Publicado: (2020)

Role of MEK partner-1 in cancer stemness through MEK/ERK pathway in cancerous neural stem cells, expressing EGFRviii
por: Kwon, Soo-Jung, et al.
Publicado: (2017)

Inactivation of PP2A by a recurrent mutation drives resistance to MEK inhibitors
por: O’Connor, Caitlin M., et al.
Publicado: (2019)

Activation of STAT3 through combined SRC and EGFR signaling drives resistance to a mitotic kinesin inhibitor in glioblastoma
por: Kenchappa, Rajappa S., et al.
Publicado: (2022)

Following Nerve Injury Neuregulin-1 Drives Microglial Proliferation and Neuropathic Pain via the MEK/ERK Pathway
por: Calvo, Margarita, et al.
Publicado: (2011)

Activated MEK/ERK Pathway Drives Widespread and Coordinated Overexpression of UHRF1 and DNMT1 in Cancer cells
por: Li, Jialun, et al.
Publicado: (2019)

Re-enforcing the strategy of targeting MEK/ERK signaling to overcome acquired resistance to third generation EGFR inhibitors
por: Zhao, Wen, et al.
Publicado: (2021)

RDM1 promotes neuroblastoma growth through the RAS–Raf–MEK–ERK pathway
por: Xie, Guojin, et al.
Publicado: (2019)

PPP6C negatively regulates oncogenic ERK signaling through dephosphorylation of MEK
por: Cho, Eunice, et al.
Publicado: (2021)

Growth Inhibitory Signaling of the Raf/MEK/ERK Pathway
por: Wu, Pui-Kei, et al.
Publicado: (2020)

The MEK/ERK Module Is Reprogrammed in Remodeling Adult Cardiomyocytes
por: Thomas, Kubin, et al.
Publicado: (2020)

The MEK5/ERK5 Pathway in Health and Disease
por: Paudel, Rupesh, et al.
Publicado: (2021)

Targeting Tuberculosis and HIV Infection-Specific Regulatory T Cells with MEK/ERK Signaling Pathway Inhibitors
por: Lieske, Nora V., et al.
Publicado: (2015)

Immunomodulatory Properties of BRAF and MEK Inhibitors Used for Melanoma Therapy—Paradoxical ERK Activation and Beyond
por: Jung, Thomas, et al.
Publicado: (2021)

Src mediates cytokine-stimulated gene expression in airway myocytes through ERK MAPK
por: Singer, Cherie A, et al.
Publicado: (2011)

Src promotes cutaneous wound healing by regulating MMP-2 through the ERK pathway
por: WU, XUE, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_9rda9o6ejl0berjpd01o81vb2q